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Immunisation registryBackground: Associations between influenza infection and sleep disorders are poorly studied. We inves-
tigated if pandemic influenza infection or vaccination with Pandemrix in 2009/2010 was associated with
narcolepsy or hypersomnia in children and young adults.
Methods: We followed the Norwegian population under age 30 from January 2008 through December
2012 by linking national health registry data. Narcolepsy diagnoses were validated using hospital
records. Risks of narcolepsy or hypersomnia were estimated as adjusted hazard ratios (HRs) in Cox
regression models with influenza infection and vaccination as time-dependent exposures.
Results: Among the 1,638,526 persons under age 30 in Norway in 2009, 3.6% received a physician diag-
nosis of influenza during the pandemic, while 41.9% were vaccinated against pandemic influenza.
Between October 1st 2009 and December 31st 2012, 72 persons had onset of narcolepsy and 305 were
diagnosed with hypersomnia. The risk of a sleep disorder was associated with infection during the first
six months, adjusted HR 3.31 with 95% confidence interval [CI], 1.01–10.79 for narcolepsy and adjusted
HR 3.13 (95% CI, 1.12–8.76) for hypersomnia. The risk of narcolepsy was strongly associated with vacci-
nation during the first six months adjusted HR 17.21 (95% CI, 6.28–47.14), while the adjusted HR for
hypersomnia was 1.54 (95% CI, 0.81–2.93).
Conclusions: The study confirms an increased HR of narcolepsy following pandemic vaccination. Slightly
increased HRs of narcolepsy and hypersomnia are also seen after influenza infection. However, the role of
infection should be viewed with caution due to underreporting of influenza.
 2017 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
During the 2009 Influenza A (H1N1) pandemic, vaccination was
recommended in many countries. After the pandemic, increasing
numbers of children and young adults with complaints of exces-
sive daytime sleepiness (EDS) [1] were observed in many countries,
including Norway [2–7]. Some patients with EDS were subse-
quently diagnosed with Narcolepsy, and a causal link to immunisa-
tion with a specific ASO3 adjuvanted influenza A H1N1 vaccine
(Pandemrix) has been suggested [2–7]. EDS is a cardinal symptomin sleep disorders of central nervous origin, including narcolepsy
and idiopatic hypersomnia [1].
The etiologies of narcolepsy and idiopatic hypersomnia are
unknown [8]. Two types of narcolepsy are clinically recognized
[1]. Both present with EDS and pathological scores in multiple
sleep latency tests (MSLT). As opposed to type 2 narcolepsy, type
1 is complicated by cataplexy and low hypocretin-1 levels in cere-
brospinal fluid (CFS) [1]. Recent studies suggest that narcolepsy
type 1 is an autoimmune disease in which hypocretin-producing
neurons important in regulation of sleep are destroyed [8–10]. Less
is known about the pathophysiological mechanisms causing
narcolepsy type 2 [1].
We are not aware of any publications addressing whether
pandemic influenza/Pandemrix vaccination is associated with
hypersomnia. However, anecdotal reports of patients with hyper-
somnia who claimed compensation after Pandemrix vaccination
encouraged inclusion of this outcome in the current study.
1880 L. Trogstad et al. / Vaccine 35 (2017) 1879–1885Idiopathic hypersomnia presents with excessive sleep in absence
of other symptoms. No biological markers have been identified,
and the pathophysiology is unknown [11]. Diagnostic criteria are
defined according to the International Classification of Sleep Disor-
ders (ICSD) [1] as either daily, irrepressible need to sleep or day-
time lapses of sleep persisting for at least 3 months. The
diagnosis requires absence of cataplexy [1]. Thus the clinical fea-
tures of narcolepsy type 2 and idiopathic hypersomnia are very
similar [11].
In Norway, the vaccination campaign coincided with the peak of
the influenza pandemic. The association between influenza infec-
tion and narcolepsy is largely unknown, and the effects of exposure
to both influenza infection and vaccination have not been
described. We had the opportunity to study narcolepsy and hyper-
somnia in children and young adults using nationwide registries
including information on both influenza infection and vaccination.2. Materials and methods
2.1. Study population
The study population comprised all individuals born after 1982
who were registered in the National Registry as residents and liv-
ing in Norway on October 1st 2009, counting 1,638,526 individuals
aged 3–29 years at end of follow-up (December 31st, 2012) [12].
The study population was followed from January 2008 through
December 2012. All Norwegian citizens have a unique personal
identification number, allowing linkage of individual exposure
and outcome data from national registries, hospital records and
other data sources. The study was approved by the Regional Com-
mittee for Medical and Health Research Ethics South East and the
Norwegian Data Protection Authority. All authors vouch for the
integrity of the data and accuracy of the analysis. The manufactur-
ers of the vaccine that was analyzed had no role in the study.2.2. Datasources, exposures and outcomes
2.2.1. Influenza infection and vaccination
The main wave of the influenza A (H1N1) pandemic in Norway
lasted from October 1st to December 31st, 2009 according to influ-
enza surveillance data from the Norwegian Institute of Public
Health based on laboratory diagnoses and clinical reports [13].
Only influenza diagnoses from this peak period were included in
the analyses.
Exposure to influenza was defined either as a primary care
physician contact leading to a clinical diagnosis of influenza
according to the International Classification of Primary Care, Sec-
ond Edition (ICPC-2), code R80 [14], or as laboratory confirmed
influenza A (H1N1) pdm09 infection. Information on primary care
influenza diagnoses were provided by the Norwegian Directorate
of Health (reimbursement data) [15]. The Norwegian Directorate
of Health reimburses consultations in emergency outpatient clinics
and general practice. We used information on dates of physician
consultations for individuals receiving an influenza diagnoses in
the ICPC-2 code system.
Data on laboratory-confirmed cases of influenza were provided
by the Norwegian Surveillance System for Communicable Diseases
[13]. This registry is a nationwide system for surveillance of infec-
tious diseases based on individual records.
Influenza vaccination was offered free of charge to the entire
Norwegian population from October 19th, 2009. Individuals with
medical risk factors for severe influenza illness and complications
were prioritized for vaccination early in the campaign. Nearly all
vaccinations (97%) were administered by December 31st, 2009.
Registration of influenza vaccinations was mandatory, and the dataare considered almost complete [16]. Dates of influenza vaccina-
tion for all individuals were extracted from the Norwegian Immu-
nisation Registry [16].
2.2.2. Narcolepsy
Information on narcolepsy diagnoses, code G47.4 in the Interna-
tional Classification of Diseases, version 10 (ICD-10) from specialist
health care services during 2008–2012 was obtained from the Nor-
wegian Patient Registry (NPR) [17]. The NPR is an administrative
database to which all Norwegian hospitals and outpatient clinics
report to receive governmental reimbursement. Children with nar-
colepsy were identified by the first registration of narcolepsy (ICD-
10 code G47.4) in the NPR. In- and out-patient hospital records for
patients registered with ICD-10 code G47.4 were reviewed by two
physicians (authors SEH and LT) for case ascertainment and extrac-
tion of relevant clinical data. Narcolepsy was classified in three
levels according to the Brighton Collaboration definition (Supple-
mentary Table 1) [18]. Level 1 includes cataplexy and
hypocretin-1 deficiency corresponding to narcolepsy type1 [1].
For patients with a persistent, clinical diagnosis of narcolepsy
recorded in the hospital record but missing information on diag-
nostic criteria, a fourth level of diagnostic certainty was defined
(Supplementary Table 1). These patients were also defined as
cases. Information on month and year of symptom onset was
extracted from hospital records.
2.2.3. Hypersomnia
Information on hypersomnia (ICD-10 code G47.1) was obtained
from the NPR [17]. The date of the first registered diagnosis was
used in the main analyses since review of hospital records for
patients registered with ICD-10 code G47.1 was not feasible due
to large number of records thus timing of symptom onset could
not be obtained.
2.3. Statistical analysis
We applied a Cox proportional-hazards regression to estimate
crude and adjusted hazard ratios (HRs) of narcolepsy and hyper-
somnia, with months from October 1st 2009 as the time metric
and vaccination and influenza infection as time varying exposures.
Subjects were considered exposed to infection from the month of
first influenza diagnosis or first positive laboratory test. Hazard
ratios (HRs) after influenza infection were calculated for three
exposure periods: 6 months, 12 months, and until the end of
follow-up (December 31st, 2012). Exposure to the vaccine was
defined from the month of vaccination and HRs calculated for the
same exposure periods.
For adjusted estimates, we used a stratified Cox proportional-
hazards regression model with sex and age (categorized into the
groups 3–9 years, 10–19 years, and 20–29 years) as stratification
variables and mutual adjustment for influenza and vaccination sta-
tus. Follow-up ended at the month of emigration, death, first
symptom of narcolepsy, first diagnosis of hypersomnia or end of
follow-up, whichever occurred first. Analyses were performed with
the use of Stata 14 software, (Stata Corp. 2015. Stata Statistical
Software: Release 14. College Station, TX: StataCorp LP.).3. Results
The weekly numbers of positive influenza laboratory tests, and
vaccinations according to the pandemic peak are illustrated in
Fig. 1. Primary care contacts for influenza like illness, ILI, showed
a similar timely distribution as the weekly number of laboratory
confirmed influenza cases (results not shown in the figure). Chil-

































































Fig. 1. Temporal distributions of vaccinations by age groups, and timing of the pandemic peak shown by the weekly number of positive influenza A H1N1pdm09 virus
laboratory tests in the Norwegian population (all ages).
L. Trogstad et al. / Vaccine 35 (2017) 1879–1885 1881nation, and were mainly vaccinated after the main pandemic peak
(Fig. 1).
A clinical or laboratory-confirmed diagnosis of influenza was
recorded in 59,107 persons (3.6%). A total of 687,982 persons
(41.9%) were vaccinated (Table 1). Influenza showed little variation
across sex and age groups. However, the clinical attack rate of
influenza is likely to be much higher than recorded and it is prob-
able that subclinical and mild cases have been underreported since
they have not received health care. Vaccination coverage was
slightly higher in females and lower in the older age groups.
3.1. Narcolepsy
Narcolepsy was reported in the NPR for 216 persons under the
age of 30. Hospital records were available for review for 214 per-
sons, and the narcolepsy diagnosis was confirmed according to
the Brighton Collaboration definition or a clinical diagnosis of
narcolepsy in 130 patients (60%), among whom 71 were female.
Sixty-five (50%) of the 130 patients fulfilled the criterions corre-
sponding to narcolepsy type 1. Sixteen patients had a persistent
clinical diagnosis without fulfillment of diagnostic criteria
(Supplementary Table 1). More information on narcolepsy
characteristics, hypocretin-1 levels and cataplexy, is supplied in
the Supplementary appendix.Table 1
Vaccination coverage and influenza illness by sex and agea during the 2009 influenza
pandemic, Norway.




Total 1,638,526 3.6 41.9
Sex
Male 839,022 3.4 40.1
Female 799,504 3.7 43.9
Age
3–9 yr 404,537 3.7 52.8
10–19 yr 619,542 3.6 53.2
20–29 yr 614,447 3.5 23.4
a Age by end of follow up (December 2012).In 48 patients, symptoms of narcolepsy had started prior to
2008. Eighty-two children and young adults had new onset nar-
colepsy during the study period from 2008 to 2012. The number
with new onset narcolepsy peaked in 2010 and subsequently
declined (Fig. 2, panel A). In 72 patients, narcolepsy onset was
dated after October 1st 2009.3.2. Influenza and risk of narcolepsy
The number of children seeking medical care for influenza dur-
ing the pandemic was low, and only four patients had registered
onset of narcolepsy after a clinical diagnosis of influenza. Among
these, three were also vaccinated - two of them after they had
influenza. The HR for narcolepsy after influenza infection was
two to threefold increased (Table 2). Within the 6 months exposure
period, the adjusted HR was 3.31 (95% confidence interval [CI],
1.01–10.79). In a sensitivity analysis using date of narcolepsy diag-
nosis in the NPR instead of symptom onset as extracted from the
hospital records, the aHR for narcolepsy within the entire follow-
up period was 1.67 (95% CI, 0.68–4.12), quite similar to the aHR
using symptom onset, 1.96 (95% CI, 0.71–5.37). The time between
infection and onset of narcolepsy symptoms was between 5 and
14 months.3.3. Vaccination and risk of narcolepsy
The HR for narcolepsy was increased in children and young
adults after pandemic vaccination (Table 2), with highest estimates
within short exposure periods (adjusted HRs, 6 months: 17.21; 95%
CI, 6.28–47.14; 12 months: 8.71; 95% CI, 4.03–18.82; until the end
of follow up: 5.53; 95% CI, 3.01–10.15). In a sensitivity analysis
using date of narcolepsy diagnosis in the NPR instead of symptom
onset as extracted from the hospital records, the aHR for nar-
colepsy within the entire follow-up period was 3.93 (95% CI,
2.47–6.25), slightly lower than the aHR using symptom onset
5.53 (95% CI, 3.01–10.15).The mean time between vaccination
and onset of narcolepsy symptoms was 7.6 months (median
5 months; range: 1–28 months).
Fig. 2. Yearly counts of new onset narcolepsy (ICD10 code G47.4) in 82 children and young adults (A), and new onset hypersomnia (ICD10 code G47.1) in 415 children and
young adults (B) in Norway 2008–2012.
Table 2
Incidence Rates (IRs) and Adjusted Hazard Ratios (HRs) with 95% Confidence Intervals (CI) for Narcolepsy According to Pandemic Influenza Infection or Vaccination Status.a
Time window Narcolepsy after influenzab Narcolepsy after vaccinationc
No. of cases IRd Adjusted HRe (95% CI) No. of cases IRd Adjusted HRe (95% CI)
6 months
No 69 0.11 1(ref) 39 0.07 1(ref)
Yes 3 0.86 3.31 (1.01–10.79) 33 0.80 17.21 (6.28–47.14)
12 months
No 69 0.11 1(ref) 32 0.06 1(ref)
Yes 3 0.45 2.36 (0.73–7.61) 40 0.51 8.71 (4.03–18.82)
End of follow up
No 68 0.11 1(ref) 16 0.04 1(ref)
Yes 4 0.18 1.96 (0.71–5.37) 56 0.22 5.53 (3.01–10.15)
a Shown are hazard ratios based on 72 new cases of narcolepsy during the period October 1, 2009 - December 31, 2012 in the Norwegian population aged 3–29
(N = 1,638,526). Narcolepsy was based on the ICD-10 code G47.4 registered in the Norwegian Patient Register, and validation of diagnoses through review of hospital records.
b Influenza-like illness during the peak pandemic period and/or laboratory-confirmed pandemic influenza.
c Vaccination against pandemic influenza with Pandemrix.
d Per 100,000 person-months.
e Stratified Cox proportional-hazards regression model with sex and age (categorized into the groups 3–9 years, 10–19 years, and 20–29 years) as stratification variables
and with mutual adjustment for influenza status and vaccination status with the same exposure period.
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A total of 415 children and young adults were registered with
hypersomnia during 2008–2012. Of these, 58.4% were female.
The yearly counts of hypersomnia during 2008–2012 were increas-
ing, as illustrated in Fig. 2, panel B.3.5. Influenza and risk of hypersomnia
The HR for hypersomnia after pandemic influenza was signifi-
cantly increased only for the 6-month exposure period (aHR,3.13; 95% CI, 1.12–8.76) (Table 3). The mean time between
infection and diagnosis was 20.0 months (median: 22 months;
range: 2–35 months).3.6. Vaccination and risk of hypersomnia
The HR for hypersomnia after pandemic vaccination exposure
was significantly increased only for exposure until end of follow-
up (adjusted HR 1.83; 95% CI, 1.44–2.33) (Table 3). The mean time
between vaccination and diagnosis of hypersomnia was
22.5 months (median 24 months, range 1–37 months).
Table 3
Incidence Rates (IRs) and Adjusted Hazard Ratios (HRs) with 95% Confidence Intervals (CI) for Hypersomnia According to Pandemic Influenza Infection or Vaccination Status.a
Time window Hypersomnia after influenzab Hypersomnia after vaccinationc
No. of cases IRd Adjusted HRe (95% CI) No. of cases IRd Adjusted HRe (95% CI)
6 months
No 295 0.48 1(ref) 283 0.49 1(ref)
Yes 4 1.15 3.13 (1.12–8.76) 16 0.39 1.54 (0.81–2.93)
12 months
No 294 0.48 1(ref) 271 0.51 1(ref)
Yes 5 0.72 2.16 (0.87–5.35) 28 0.34 1.50 (0.92–2.44)
End of follow up
No 283 0.47 1(ref) 156 0.42 1(ref)
Yes 16 0.74 1.64 (0.99–2.72) 143 0.57 1.83 (1.44–2.33)
a Shown are hazard ratios based on 305 new cases of hypersomnia during the period October 1, 2009 - December 31, 2012 in the Norwegian population aged 3–29
(N = 1,638,526). Six cases of hypersomnia were registered with first diagnosis in October 2009 and were excluded from the analysis by default (zero follow-up time).
Hypersomnia was based on the ICD-10 code G47.1 registered in the Norwegian Patient Register.
b Influenza-like illness during the peak pandemic period and/or laboratory-confirmed pandemic influenza.
c Vaccination against pandemic influenza with Pandemrix.
d Per 100,000 person-months.
e Stratified Cox proportional-hazards regression model with sex and age (categorized into the groups 3–9 years, 10–19 years, and 20–29 years) as stratification variables
and with mutual adjustment for influenza status and vaccination status with the same exposure period.
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The combined effect of exposure to influenza and vaccination
was estimated in a separate analysis, and is presented in Supple-
mentary Table 2. The HR for narcolepsy after exposure to both vac-
cination and infection was increased as compared to vaccination
alone, adjusted HR 18.46 (95% CI, 3.81–89.58) versus adjusted HR
9.11 (95% CI, 4.08–20.37). However, the estimates are based on
small numbers, and the confidence intervals are wide and overlap-
ping (Supplementary Table 2). The adjusted HR for hypersomnia
after combined exposure to vaccination and infection was also sig-
nificantly increased as compared to vaccination alone (adjusted
HR, 6.46; 95% CI, 1.99–21.03) (Supplementary Table 2).4. Discussion
Using registry data in a complete national population setting,
we confirm previous reports of an association between vaccination
with Pandemrix and later development of narcolepsy [2–7]. We
also report an increased HR for narcolepsy after influenza infection,
and for hypersomnia following both influenza infection and vacci-
nation. Narcolepsy cases were confirmed by review of hospital
records, and the more than half of all cases fulfilled the criteria
for narcolepsy type 1 [1].
The HR for narcolepsy was higher in the first months after vac-
cination or influenza infection, and declined with longer exposure
periods. For hypersomnia, the HR was higher shortly after influ-
enza infection, while HRs following vaccination tended to increase
with longer exposure periods. We believe this is the first study to
assess risks of narcolepsy and hypersomnia according to length
of exposure periods within the same dataset. The change in risk
estimates with the length of the exposure periods may possibly
explain the differences in estimated risks in previously published
papers on pandemic vaccination and narcolepsy [2–7].
Although the association between influenza infection and nar-
colepsy has not previously been studied in large cohorts with high
vaccination coverage, prior observations have suggested increased
risks following the influenza pandemic in settings with low (Den-
mark) or very low (China) vaccination coverage [3,19]. In the four
months following the 2009 influenza pandemic peak, the incidence
rate of narcolepsy in China sharply increased in a mainly unvacci-
nated population, and then returned to previous rates in the fol-
lowing timeperiod [20]. Data in the present study showed a
similar pattern. The possibility that infections are associated withoutbreaks of narcolepsy is also suggested by the seasonal patterns
of narcolepsy onset in China, which has revealed a 6-fold-
increase in spring and summer versus winter, suggesting that win-
ter infections such as influenza may trigger the autoimmune attack
on hypocretin-producing neurons [19]. However, infections by
other infectious agents such as Streptococci pyogenes have also
been proposed to trigger narcolepsy [21].
A genetic susceptibility to narcolepsy linked to human leuko-
cyte antigen (HLA) DQB1 has been established [22]. Yet, only about
25% of affected monozygotic twins are concordant for narcolepsy,
pointing to a significant impact of environmental factors [23]. It
is conceivable that common antigens in the influenza A (H1N1)
pdm09 virus and the pandemic vaccine Pandemrix may trigger
narcolepsy via autoimmune mechanisms [24,25]. The current
study may also lend support to the hypothesis that infections can
trigger narcolepsy.
The vaccination campaign in Norway coincided with the pan-
demic influenza peak in 2009. Disentangling the effects of infection
and vaccination requires individual exposure measurements. The
risk estimates in this type of study seem dependent on the expo-
sure period used, and comparing results from different studies
may be difficult. Lack of control for concurrent influenza infection
may further make the interpretation difficult.
Since the whole population was included in the current study,
selection bias is not expected to have influenced our results. How-
ever, underreporting of influenza is present. A clinical diagnosis of
influenza during the pandemic was recorded in only 3.6% of the
study population while estimates based on national influenza
surveillance data suggest a clinical attack rate of approximately
30%, with the highest disease rates among children aged 0–
14 years [26]. Many influenza infections may have been subclinical
or mild, and only a proportion of symptomatic patients received
health care. Thus detection bias due to underreporting of influenza
is likely. We demonstrated that most children and young adults
were vaccinated after the pandemic peak. Hence, it is likely that
a large proportion, perhaps up to 30%, had clinical or sub-clinical
influenza infection prior to or at the time of vaccination [26]. Con-
sequently, it is plausible that a proportion of patients recorded
with narcolepsy or hypersomnia following vaccination were
indeed exposed to both influenza and vaccine.
Underreporting of an exposure in an observational study usu-
ally biases the relative risks towards no association, as may be
the case for influenza in our study. Moreover, misclassification of
double exposed individuals to the vaccinated category due to
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cination, as discussed in two recent simulation studies on influenza
vaccination and narcolepsy [27,28]. The same may be true for
hypersomnia. Although information on influenza infection was
likely to be underreported in the current study, the HRs of nar-
colepsy and hypersomnia after combined exposure to vaccination
and infection was significantly increased.
Registration of vaccination was mandatory [16] and less prone
to detection bias. Differential information bias of the association
between vaccination and narcolepsy is unlikely during the first
6 months after the pandemic peak, since the excess occurrence of
narcolepsy cases first became publicly known in September 2010.
Thereafter, massive public attention was drawn to narcolepsy as
a possible adverse event following vaccination, thus increasing
the risk of differential reporting of vaccinated patients.
Only validated narcolepsy cases were included in the analyses,
reducing misclassification. Furthermore, time of symptom onset
was extracted from hospital records, possibly reducing misclassifi-
cation due to recall bias. Review of hospital records showed a pos-
itive predictive value of only 60% for narcolepsy according to the
Brighton criteria which emphasizes the importance of validating
register data, in particular for rare and serious outcomes with long
diagnostic trajectories.
The clinical features of hypersomnia may be heterogeneous and
of variable severity as previously described [11,29]. For most
patients symptoms remain stable over years, although sponta-
neous remission was described for hypersomnia but not for nar-
colepsy in one study [30]. Onset may span from childhood
onwards. To date, prevalence studies of idiopathic hypersomnia
have not been conducted [11]. We are not aware of other publica-
tions concerning the association between pandemic influenza/
Pandemrix vaccination and hypersomnia, and we can only specu-
late that this has not been looked for by other researchers. How-
ever, anecdotal reports of patients with hypersomnia claiming
compensation following Pandemrix vaccination encouraged inclu-
sion of this outcome in the current study – even if validation of the
hypersomnia diagnosis in the NPR was not feasible. The diagnosis
of hypersomnia was not reviewed in our study, and the accuracy of
this diagnosis in the NPR has not been established otherwise. Thus,
patients with true narcolepsy may have been misclassified as hav-
ing hypersomnia upon referral to specialist health care.
The diagnosis of idiopathic hypersomnia requires absence of
cataplexy and MSLT showing no or less than two sudden onset
REM sleep episodes (SOREMs) [1]. Thus the clinical features of nar-
colepsy type 2 and idiopathic hypersomnia are very similar. The
polysomnographic features of the two conditions are only sepa-
rated by the SOREM criteria: Less than two in idiopathic hypersom-
nia, two or more in narcolepsy type 2 [11]. Considering the
questionable test-retest reliability of MSLT [31,32], it has been
questioned whether there is a difference between the two [11].
The different risk patterns for hypersomnia and narcolepsy accord-
ing to influenza or vaccination in our study may lend support to
the two as different biological entities. However, more than half
of all narcolepsy cases in the current study fulfilled the criteria
for narcolepsy type 1, which is likely to be caused by destruction
of hypocretin-producing neurons and possibly triggered by vacci-
nation or infection. This possible difference in pathogenic mecha-
nism may explain the discrepancy in pattern of response for
narcolepsy and hypersomnia. The relatively long observation time
in the study allowed thorough examination of suspected nar-
colepsy cases, but misclassification of patients with true nar-
colepsy as hypersomnia still cannot be completely ruled out, in
particular among patients diagnosed towards the end of the obser-
vation time. This may explain why the HR for hypersomnia after
vaccination is slightly elevated only at the end of follow up, and
to a much lower degree than for narcolepsy.5. Conclusions
In summary, we confirm a statistically significant association
between vaccination with Pandemrix and narcolepsy in complete
population data. Although a slightly increased HR of narcolepsy
and hypersomnia is seen after influenza infection, overall, the role
of influenza in the development of narcolepsy and hypersomnia
should be viewed with caution due to underreporting of influenza.
However, it is remarkable that when both infection and vaccina-
tion are present, HRs are increased, suggesting a synergy. Thus,
the HR for narcolepsy after vaccination may be inflated since many
vaccinated subjects probably were infected before vaccination.
For a full understanding of the association between infection,
vaccination and neurological disease a large cohort would need
to be established- with repeated exposure assessments, including
silent infections, and clinical follow-up of suspected cases. Fre-
quent exposure assessments and long-term commitment of cohort
participants are likely to make such a study costly and logistically
challenging to undertake. In some countries, like Norway, national
health registers represent valuable data sources. However, infor-
mation on common exposures that only to a small extent requires
medical attention, like influenza, is underreported in health reg-
istries, and this makes studies of rare outcomes like narcolepsy
suboptimal. Still, in our opinion, exploitation of population- based
registries and surveillance systems should be continued and efforts
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